
Prostate Cancer
Latest News

Latest Videos

CME Content
More News

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

The Department of Health and Human Services has turned down a request to override the patent for prostate cancer drug enzalutamide (Xtandi) so that it can be sold to a broader base of patients at a reduced price.

In metastatic castration-resistant prostate cancer, pain and hemoglobin levels, PSA levels, and ECOG performance status may predict which patients will be able to receive the recommended 6-dose regimen of radium-223 dichloride (Xofigo).

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Richard G. Stock, MD, discusses the ideal patient for radium-223 dichloride (Xofigo), its proper sequencing with metastatic castration-resistant prostate cancer, and the future outlook for the therapy.

Although androgen deprivation therapy has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether it causes clinically significant depression.

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Researchers are hoping the results of a late-stage efficacy and safety study of apalutamide in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.

A combination regimen involving abiraterone acetate (Zytiga) and low-dose prednisone demonstrated a median time to radiographic progression of 41.4 months, as well as a median time to prostate-specific antigen progression of 28.7 months, in men with nonmetastatic castration-resistant prostate cancer.






































































